Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Genzyme/Isis Build Simple, No Fuss Case For Weekly Cholesterol Injectable Kynamro

Executive Summary

Genzyme and Isis are playing up mipomersen’s intrinsic qualities as they prepare to go head-to-head against Aegerion’s Juxtapid in the small homozygous familial hypercholesterolemia market. Kynamro also will carry a price tag that is $119,000 less than Juxtapid’s.

You may also be interested in...



Isis Says Ultra-Orphan Use Promises Speedier Approval For ISIS-APOCIIIRx

Sharing data for just three patients with the ultra-rare genetic disease familial chylomicronemia, Isis says starting with this indication will allow market entry one year earlier.

Isis Says Ultra-Orphan Use Promises Speedier Approval For ISIS-APOCIIIRx

Sharing data for just three patients with the ultra-rare genetic disease familial chylomicronemia, Isis says starting with this indication will allow market entry one year earlier.

Business News, In Brief

Isis banks on milestones from partners, Onyx rakes in higher-than-expected revenues from Kyprolis, Seattle Genetics announces trial delays, and other news from biopharma’s first quarter.

Related Content

Topics

Related Companies

Latest News
UsernamePublicRestriction

Register

PS055085

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel